<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med Res</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med Res</journal-id><journal-id journal-id-type="publisher-id">Elmer Press</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine Research</journal-title></journal-title-group><issn pub-type="ppub">1918-3003</issn><issn pub-type="epub">1918-3011</issn><publisher><publisher-name>Elmer Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23864922</article-id><article-id pub-id-type="pmc">3712888</article-id><article-id pub-id-type="doi">10.4021/jocmr1489w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Efficacy of Vitamin C Vaginal Tablets as Prophylaxis for Recurrent Bacterial Vaginosis: A Randomised, Double-Blind, Placebo-Controlled Clinical Trial</article-title><alt-title alt-title-type="short">Vitamin C Vaginal Tablets in Recurrent Bacterial Vaginosis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Krasnopolsky</surname><given-names>Vladislav N.</given-names></name><xref ref-type="aff" rid="Aa">a</xref></contrib><contrib contrib-type="author"><name><surname>Prilepskaya</surname><given-names>Vera N.</given-names></name><xref ref-type="aff" rid="Ab">b</xref></contrib><contrib contrib-type="author"><name><surname>Polatti</surname><given-names>Franco</given-names></name><xref ref-type="aff" rid="Ac">c</xref></contrib><contrib contrib-type="author"><name><surname>Zarochentseva</surname><given-names>Nina V.</given-names></name><xref ref-type="aff" rid="Aa">a</xref></contrib><contrib contrib-type="author"><name><surname>Bayramova</surname><given-names>Guldana R.</given-names></name><xref ref-type="aff" rid="Ab">b</xref></contrib><contrib contrib-type="author"><name><surname>Caserini</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="Ad">d</xref></contrib><contrib contrib-type="author"><name><surname>Palmieri</surname><given-names>Renata</given-names></name><xref ref-type="aff" rid="Ad">d</xref><xref ref-type="corresp" rid="CORe">e</xref></contrib></contrib-group><aff id="Aa"><label>a</label>Research Centre of Obstetrics and Gynaecology of Moscow Region, Moscow, Russia</aff><aff id="Ab"><label>b</label>Research Centre of Obstetrics, Gynaecology and Perinatology of Rosmedtechnologies, Moscow, Russia</aff><aff id="Ac"><label>c</label>University of Pavia - “Medicine and Surgery” Faculty, Pavia, Italy</aff><aff id="Ad"><label>d</label>Scientific Department, Polichem SA, Lugano, Switzerland</aff><author-notes><corresp id="CORe"><label>e</label>Corresponding author: Renata Palmieri, Via Senago 42/D, CH-6912 Lugano, Switzerland. Email: <email> renata.palmieri@polichem.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>21</day><month>6</month><year>2013</year></pub-date><volume>5</volume><issue>4</issue><fpage>309</fpage><lpage>315</lpage><history><date date-type="accepted"><day>10</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>Copyright 2013, Krasnopolsky et al.</copyright-statement><copyright-year>2013</copyright-year><license license-type="open access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="a1"><title><offsets xml_i="3893" xml_f="3903" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3914" xml_f="4580" txt_i="22" txt_f="688">The aetiology of bacterial vaginosis (BV) is still unclear but it is currently considered to be a synergistic polymicrobial syndrome. BV can often arise as a chronic or recurrent disease. The reason for such recurrences is not well elucidated. Previous studies have suggested that vaginal vitamin C may be a useful treatment in reducing recurrence rate, by increasing vaginal acidification and thereby making up for the decrease in hydrogen peroxide that results from a reduction in the number of lactobacilli present. Based on the above-mentioned consideration, a study was performed that aimed to evaluate the effect of vitamin C in the prophylaxis of BV relapses.</offsets></p></sec><sec id="a2"><title><offsets xml_i="4610" xml_f="4617" txt_i="690" txt_f="697">Methods</offsets></title><p><offsets xml_i="4628" xml_f="5113" txt_i="698" txt_f="1183">This was a randomised, double-blind, placebo-controlled, parallel-group clinical trial. One hundred and forty-two women, after having been cured from a recent episode of BV by either metronidazole or clindamycin, were randomised to receive vitamin C (74 patients) or placebo (68 patients) as prophylaxis for six monthly cycles, starting within 24 hours of the determination of ‘BV cure’. The patients applied one vaginal tablet once a day for 6 consecutive days per month after menses.</offsets></p></sec><sec id="a3"><title><offsets xml_i="5143" xml_f="5150" txt_i="1185" txt_f="1192">Results</offsets></title><p><offsets xml_i="5161" xml_f="5628" txt_i="1193" txt_f="1660">The rate of BV recurrence during the first 3 months was considerably lower in the vitamin C group (6.8%) than in the placebo (14.7%) group. Considering a 6-month treatment period, the recurrence rate in the vitamin C group (16.2%) was significantly lower (P = 0.024) than in the placebo group (32.4%). Moreover, at the same time point, the survival analysis of Kaplan Meyer was significant in favour of the vitamin C group compared with the placebo group (P = 0.029).</offsets></p></sec><sec id="a4"><title><offsets xml_i="5658" xml_f="5669" txt_i="1662" txt_f="1673">Conclusions</offsets></title><p><offsets xml_i="5680" xml_f="5899" txt_i="1674" txt_f="1893">The study showed that regular use of 250 mg ascorbic acid vaginal tablets on 6 days per month for 6 months after successful treatment of bacterial vaginosis halves the risk of recurrence from 32.4% to 16.2% (P = 0.024).</offsets></p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Bacterial vaginosis</kwd><kwd>Bacterial vaginosis prophylaxis</kwd><kwd>Vitamin C vaginal tablets</kwd><kwd>Ascorbic acid vaginal tablets</kwd></kwd-group></article-meta></front><body><sec id="s1"><title><offsets xml_i="6164" xml_f="6176" txt_i="1902" txt_f="1914">Introduction</offsets></title><p><offsets xml_i="6187" xml_f="6300" txt_i="1915" txt_f="2028">Bacterial vaginosis (BV) is a common condition that affects almost one-third of women of childbearing age (29%) [</offsets><xref ref-type="bibr" rid="R01"><offsets xml_i="6332" xml_f="6333" txt_i="2028" txt_f="2029">1</offsets></xref><offsets xml_i="6340" xml_f="6543" txt_i="2029" txt_f="2232">]. In Caucasian women, the prevalence is 5% to 15%; in African and black American women, it is 45% to 55%; and in Asian women the prevalence is less well studied, but in general it is around 20% to 30% [</offsets><xref ref-type="bibr" rid="R02"><offsets xml_i="6575" xml_f="6576" txt_i="2232" txt_f="2233">2</offsets></xref><offsets xml_i="6583" xml_f="6585" txt_i="2233" txt_f="2235">].</offsets></p><p><offsets xml_i="6592" xml_f="6734" txt_i="2236" txt_f="2378">The aetiology of BV is still unclear but it is currently considered to be a synergistic polymicrobial syndrome, characterised by depletion of </offsets><italic><offsets xml_i="6742" xml_f="6755" txt_i="2378" txt_f="2391">Lactobacillus</offsets></italic><offsets xml_i="6764" xml_f="6875" txt_i="2391" txt_f="2502"> spp and an intense increase (100- to 1,000-fold above normal levels) in vaginal anaerobic bacteria, including </offsets><italic><offsets xml_i="6883" xml_f="6904" txt_i="2502" txt_f="2523">Gardnerella vaginalis</offsets></italic><offsets xml_i="6913" xml_f="6915" txt_i="2523" txt_f="2525">, </offsets><italic><offsets xml_i="6923" xml_f="6933" txt_i="2525" txt_f="2535">Prevotella</offsets></italic><offsets xml_i="6942" xml_f="6979" txt_i="2535" txt_f="2572"> spp, anaerobic gram-positive cocci, </offsets><italic><offsets xml_i="6987" xml_f="6997" txt_i="2572" txt_f="2582">Mobiluncus</offsets></italic><offsets xml_i="7006" xml_f="7012" txt_i="2582" txt_f="2588"> spp, </offsets><italic><offsets xml_i="7020" xml_f="7038" txt_i="2588" txt_f="2606">Mycoplasma hominis</offsets></italic><offsets xml_i="7047" xml_f="7052" txt_i="2606" txt_f="2611"> and </offsets><italic><offsets xml_i="7060" xml_f="7079" txt_i="2611" txt_f="2630">Atopobium vaginalis</offsets></italic><offsets xml_i="7088" xml_f="7090" txt_i="2630" txt_f="2632"> [</offsets><xref ref-type="bibr" rid="R03"><offsets xml_i="7122" xml_f="7123" txt_i="2632" txt_f="2633">3</offsets></xref><offsets xml_i="7130" xml_f="7132" txt_i="2633" txt_f="2635">, </offsets><xref ref-type="bibr" rid="R04"><offsets xml_i="7164" xml_f="7165" txt_i="2635" txt_f="2636">4</offsets></xref><offsets xml_i="7172" xml_f="7246" txt_i="2636" txt_f="2710">], leading to a replacement of lactobacilli and an increase in vaginal pH.</offsets></p><p><offsets xml_i="7253" xml_f="7445" txt_i="2711" txt_f="2903">BV can often arise as a chronic or recurrent disease and the reason for recurrences is not well known. Based on fluorescence in situ hybridisation of vaginal biopsy specimens, Mendling et al [</offsets><xref ref-type="bibr" rid="R04"><offsets xml_i="7477" xml_f="7478" txt_i="2903" txt_f="2904">4</offsets></xref><offsets xml_i="7485" xml_f="7632" txt_i="2904" txt_f="3051">] have demonstrated that BV is associated with the development of an adherent polymicrobial biofilm that is highly organised and contains abundant </offsets><italic><offsets xml_i="7640" xml_f="7661" txt_i="3051" txt_f="3072">Gardnerella vaginalis</offsets></italic><offsets xml_i="7670" xml_f="7795" txt_i="3072" txt_f="3197"> on the vaginal epithelium. Bacterial biofilms have recently been associated with several recalcitrant infections (involving </offsets><italic><offsets xml_i="7803" xml_f="7819" txt_i="3197" txt_f="3213">Escherichia coli</offsets></italic><offsets xml_i="7828" xml_f="7830" txt_i="3213" txt_f="3215">, </offsets><italic><offsets xml_i="7838" xml_f="7857" txt_i="3215" txt_f="3234">Helicobacter pylori</offsets></italic><offsets xml_i="7866" xml_f="7871" txt_i="3234" txt_f="3239"> and </offsets><italic><offsets xml_i="7879" xml_f="7901" txt_i="3239" txt_f="3261">Pseudomonas aeruginosa</offsets></italic><offsets xml_i="7910" xml_f="7913" txt_i="3261" txt_f="3264">) [</offsets><xref ref-type="bibr" rid="R05"><offsets xml_i="7945" xml_f="7946" txt_i="3264" txt_f="3265">5</offsets></xref><offsets xml_i="7953" xml_f="8204" txt_i="3265" txt_f="3516">]. The biofilm enhances bacterial attachment to epithelial surfaces, allows bacteria to reach much higher concentrations than in luminal fluids, and prevents the drugs from reaching the bacteria, which reside in the film in a quiescent, latent state [</offsets><xref ref-type="bibr" rid="R06"><offsets xml_i="8236" xml_f="8237" txt_i="3516" txt_f="3517">6</offsets></xref><offsets xml_i="8244" xml_f="8327" txt_i="3517" txt_f="3600">]. This observation might provide an explanation of the high rates of BV relapses [</offsets><xref ref-type="bibr" rid="R07"><offsets xml_i="8359" xml_f="8360" txt_i="3600" txt_f="3601">7</offsets></xref><offsets xml_i="8367" xml_f="8369" txt_i="3601" txt_f="3603">, </offsets><xref ref-type="bibr" rid="R08"><offsets xml_i="8401" xml_f="8402" txt_i="3603" txt_f="3604">8</offsets></xref><offsets xml_i="8409" xml_f="8428" txt_i="3604" txt_f="3623">]. The presence of </offsets><italic><offsets xml_i="8436" xml_f="8453" txt_i="3623" txt_f="3640">Atopobium vaginae</offsets></italic><offsets xml_i="8462" xml_f="8488" txt_i="3640" txt_f="3666"> strictly associated with </offsets><italic><offsets xml_i="8496" xml_f="8517" txt_i="3666" txt_f="3687">Gardnerella vaginalis</offsets></italic><offsets xml_i="8526" xml_f="8596" txt_i="3687" txt_f="3757"> in the persistent and adherent bacterial biofilm has been confirmed [</offsets><xref ref-type="bibr" rid="R04"><offsets xml_i="8628" xml_f="8629" txt_i="3757" txt_f="3758">4</offsets></xref><offsets xml_i="8636" xml_f="8704" txt_i="3758" txt_f="3826">], and seems to be the main reason for the failure of BV treatment [</offsets><xref ref-type="bibr" rid="R09"><offsets xml_i="8736" xml_f="8737" txt_i="3826" txt_f="3827">9</offsets></xref><offsets xml_i="8744" xml_f="8782" txt_i="3827" txt_f="3865">]. Although some authors suggest that </offsets><italic><offsets xml_i="8790" xml_f="8807" txt_i="3865" txt_f="3882">Atopobium vaginae</offsets></italic><offsets xml_i="8816" xml_f="8898" txt_i="3882" txt_f="3964"> may play a role in lowering the vaginal pH level through lactic acid production [</offsets><xref ref-type="bibr" rid="R10"><offsets xml_i="8930" xml_f="8932" txt_i="3964" txt_f="3966">10</offsets></xref><offsets xml_i="8939" xml_f="8972" txt_i="3966" txt_f="3999">], Marconi et al have found that </offsets><italic><offsets xml_i="8980" xml_f="8997" txt_i="3999" txt_f="4016">Atopobium vaginae</offsets></italic><offsets xml_i="9006" xml_f="9070" txt_i="4016" txt_f="4080"> content strongly increases if the vaginal pH is 4.9 or higher [</offsets><xref ref-type="bibr" rid="R11"><offsets xml_i="9102" xml_f="9104" txt_i="4080" txt_f="4082">11</offsets></xref><offsets xml_i="9111" xml_f="9292" txt_i="4082" txt_f="4263">]. Therefore, they suggest that strains of this bacterium may have different capacities of lactic acid production but not to a significant level to safeguard the vaginal microflora.</offsets></p><p><offsets xml_i="9299" xml_f="9514" txt_i="4264" txt_f="4479">Vaginal vitamin C is available as silicon-coated tablets containing 250 mg ascorbic acid. This formulation is able to release the vitamin over hours, allowing a statistically significant vaginal pH-lowering effect [</offsets><xref ref-type="bibr" rid="R12"><offsets xml_i="9546" xml_f="9548" txt_i="4479" txt_f="4481">12</offsets></xref><offsets xml_i="9555" xml_f="9680" txt_i="4481" txt_f="4606">]. The efficacy of vaginal vitamin C in relieving BV signs and symptoms has been confirmed in two studies by Petersen et al [</offsets><xref ref-type="bibr" rid="R13"><offsets xml_i="9712" xml_f="9714" txt_i="4606" txt_f="4608">13</offsets></xref><offsets xml_i="9721" xml_f="9723" txt_i="4608" txt_f="4610">, </offsets><xref ref-type="bibr" rid="R14"><offsets xml_i="9755" xml_f="9757" txt_i="4610" txt_f="4612">14</offsets></xref><offsets xml_i="9764" xml_f="9929" txt_i="4612" txt_f="4777">]. Moreover, Abbaspour et al have showed that the efficacy of vaginal vitamin C in BV treatment is non-inferior to that of standard local metronidazole gel therapy [</offsets><xref ref-type="bibr" rid="R15"><offsets xml_i="9961" xml_f="9963" txt_i="4777" txt_f="4779">15</offsets></xref><offsets xml_i="9970" xml_f="9972" txt_i="4779" txt_f="4781">].</offsets></p><p><offsets xml_i="9979" xml_f="10224" txt_i="4782" txt_f="5027">The main goal of BV therapy and, in particular, of BV prevention is to keep the vaginal pH at 4.5 or lower, in order to prevent the overgrowth of pathogens until the normal lactobacilli are re-established and able to maintain the pH themselves [</offsets><xref ref-type="bibr" rid="R16"><offsets xml_i="10256" xml_f="10258" txt_i="5027" txt_f="5029">16</offsets></xref><offsets xml_i="10265" xml_f="10329" txt_i="5029" txt_f="5093">]. Anaerobes grow poorly at pH 4.5 or lower; the optimum pH for </offsets><italic><offsets xml_i="10337" xml_f="10347" txt_i="5093" txt_f="5103">Prevotella</offsets></italic><offsets xml_i="10356" xml_f="10365" txt_i="5103" txt_f="5112"> spp and </offsets><italic><offsets xml_i="10373" xml_f="10394" txt_i="5112" txt_f="5133">Gardnerella vaginalis</offsets></italic><offsets xml_i="10403" xml_f="10850" txt_i="5133" txt_f="5580"> growth is 6 - 7. In vitro studies show that the concentrations of these bacteria increase with increasing pH, but both are susceptible to low pH. An ideal way to manage recurrent BV would be to maintain the vaginal pH at 4.5 with a prophylactic treatment that is able to control the overgrowth of bacteria. In this context, a viable therapeutic agent could be ascorbic acid, as it may able to help re-establish and maintain the vaginal ecosystem.</offsets></p><p><offsets xml_i="10857" xml_f="11106" txt_i="5581" txt_f="5830">Based on the above-mentioned considerations, the present study aimed to evaluate the potential effect of vitamin C, well known to have a vaginal pH-lowering effect, in the prophylaxis of BV relapses in patients who have been cured from a BV episode.</offsets></p></sec><sec sec-type="materials|methods" id="s2"><title><offsets xml_i="11165" xml_f="11186" txt_i="5832" txt_f="5853">Materials and Methods</offsets></title><sec id="s2a"><title><offsets xml_i="11215" xml_f="11221" txt_i="5854" txt_f="5860">Ethics</offsets></title><p><offsets xml_i="11232" xml_f="11443" txt_i="5861" txt_f="6072">The study was fully Good Clinical Practice (GCP) compliant and was reviewed and approved by all relevant Independent Ethics Committees. All patients provided written informed consent prior to entering the study.</offsets></p></sec><sec id="s2b"><title><offsets xml_i="11474" xml_f="11495" txt_i="6074" txt_f="6095">Design and treatments</offsets></title><p><offsets xml_i="11506" xml_f="12009" txt_i="6096" txt_f="6599">This was a multicentre, randomised, double-blind, placebo-controlled, parallel-group clinical trial. The patient population, recruited in nine European sites located in Italy, Germany, Russia, Ukraine, Portugal and the Netherlands, consisted of 142 out-patient women, aged between 18 and 50 years, with history of recurrent episodes of BV defined as at least two acute episodes in the last 12 months. The BV diagnosis was based on the contemporary presence of at least three out of four Amsel criteria [</offsets><xref ref-type="bibr" rid="R17"><offsets xml_i="12041" xml_f="12043" txt_i="6599" txt_f="6601">17</offsets></xref><offsets xml_i="12050" xml_f="12251" txt_i="6601" txt_f="6796">]: vaginal discharge, pH of vaginal fluid &gt; 4.5, amine (fishy) odour of vaginal discharge after addition of 10% KOH (whiff test) and the presence of clue cells (&gt; 20%) on microscopic examination.</offsets></p><p><offsets xml_i="12258" xml_f="12343" txt_i="6797" txt_f="6882">Patients with diagnosis of human immunodeficiency virus (HIV) infection, gonorrhoea, </offsets><italic><offsets xml_i="12351" xml_f="12369" txt_i="6882" txt_f="6900">Treponema pallidum</offsets></italic><offsets xml_i="12378" xml_f="12380" txt_i="6900" txt_f="6902">, </offsets><italic><offsets xml_i="12388" xml_f="12404" txt_i="6902" txt_f="6918">Herpes genitalis</offsets></italic><offsets xml_i="12413" xml_f="12512" txt_i="6918" txt_f="7017">, trichomoniasis and/or candidiasis, or concomitantly treated with immunosuppressant, antibiotics, </offsets><italic><offsets xml_i="12520" xml_f="12533" txt_i="7017" txt_f="7030">Lactobacillus</offsets></italic><offsets xml_i="12542" xml_f="12625" txt_i="7030" txt_f="7113"> preparations, acidifying agents, disinfectants, or vaginal douching were excluded.</offsets></p><p><offsets xml_i="12632" xml_f="12717" txt_i="7114" txt_f="7199">Eligible women, cured (confirmed by the absence of three out of four Amsel criteria [</offsets><xref ref-type="bibr" rid="R17"><offsets xml_i="12749" xml_f="12751" txt_i="7199" txt_f="7201">17</offsets></xref><offsets xml_i="12758" xml_f="13274" txt_i="7201" txt_f="7717">]) from an episode of BV by a course of either metronidazole or clindamycin, were randomly (1:1) assigned to receive 250 mg ascorbic acid vaginal tablets or placebo as prophylaxis for six monthly cycles, starting within 24 hours from the determination of ‘BV cure’. The patients applied one vaginal tablet once a day for 6 consecutive days per month after menses. The women were instructed to insert the tablets deep into the vagina at bedtime and were supplied with 250 mg ascorbic acid tablets or matching placebo.</offsets></p><p><offsets xml_i="13281" xml_f="13447" txt_i="7718" txt_f="7884">The overall prophylaxis was set by six cycles of applications but, when the first BV relapse occurred (confirmed by the presence of three out of four Amsel criteria [</offsets><xref ref-type="bibr" rid="R17"><offsets xml_i="13479" xml_f="13481" txt_i="7884" txt_f="7886">17</offsets></xref><offsets xml_i="13488" xml_f="13538" txt_i="7886" txt_f="7936">]), the patients were discontinued from the study.</offsets></p></sec><sec id="s2c"><title><offsets xml_i="13569" xml_f="13580" txt_i="7938" txt_f="7949">Assessments</offsets></title><p><offsets xml_i="13591" xml_f="14181" txt_i="7950" txt_f="8540">Clinical visits were conducted at the end of each cycle, within 3 days of the end of the treatment, and 1 month after the end of the last cycle (final visit). The diagnosis of BV was documented by collecting two specimens of vaginal discharge: the first sample for microscopic examination (detection of clue cells) of the fresh smear and the second one for the whiff test. Moreover, BV signs and symptoms were recorded (itching, burning, dysuria, odour, erythema, oedema, and fissures) and scored by means of a four-point scale as follows: 0 = absent, 1 = mild, 2 = moderate and 3 = severe.</offsets></p><p><offsets xml_i="14188" xml_f="14300" txt_i="8541" txt_f="8653">Vaginal pH measurements were performed by the patients themselves using a pH-measuring device, namely pHem-Alert</offsets><sup><offsets xml_i="14305" xml_f="14306" txt_i="8653" txt_f="8654">®</offsets></sup><offsets xml_i="14312" xml_f="14499" txt_i="8654" txt_f="8841"> (Gynex Corporation, USA) during each cycle: before and 12 hours after the first application, 12 hours after the last application and during the application-free period on days 10 and 15.</offsets></p><p><offsets xml_i="14506" xml_f="14625" txt_i="8842" txt_f="8961">The primary efficacy variable of the study was the time to the first BV relapse diagnosed according to Amsel criteria [</offsets><xref ref-type="bibr" rid="R17"><offsets xml_i="14657" xml_f="14659" txt_i="8961" txt_f="8963">17</offsets></xref><offsets xml_i="14666" xml_f="15193" txt_i="8963" txt_f="9490">]. Secondary end-points were the evaluation of the pH-lowering effect of vitamin C, the evaluation of the frequency of BV sign and symptoms during the prophylaxis period, global assessment of the acceptability of the product by investigators and patients and the evaluation of the safety of vitamin C. The acceptability and tolerability of the product were evaluated by the patient and the investigator, respectively, according to the following five-point scale: 1 = very good, 2 = good, 3 = fair, 4 = poor and 5 = intolerance.</offsets></p></sec><sec id="s2d"><title><offsets xml_i="15224" xml_f="15244" txt_i="9492" txt_f="9512">Statistical analysis</offsets></title><p><offsets xml_i="15255" xml_f="15838" txt_i="9513" txt_f="10096">All randomised patients who fulfilled the inclusion/exclusion criteria and had received at least one dose of the study medication were included in the intention-to-treat (ITT) analysis. In case of premature discontinuation or missing data in completed patients, the last observation carried forward approach (LOCF) was used and the final available observation was considered as an end-point value. All enrolled patients were considered as the safety population. The sample size was determined based on the chi-square test and the power was 85% to detect an odds ratio (O.R.) of 0.26.</offsets></p><p><offsets xml_i="15845" xml_f="16245" txt_i="10097" txt_f="10497">The randomisation list was computer-generated in blocks of four with treatments balanced (1:1) within blocks, by the Biometry Department of Medi Service s.r.l., Italy, using the SAS Package 8.2, validated routine from the Computerized System Validation Process. Variables of an ordinate classification and dichotomous type were tested by the chi-square test according to the Mantel-Hanszel extension.</offsets></p><p><offsets xml_i="16252" xml_f="16640" txt_i="10498" txt_f="10886">The proportion of subjects free of BV relapse after three or six cycles of prophylaxis was calculated considering the time from randomisation to the occurrence of the first event or to the last visit if the event did not occur. The event-free survival curve (EFS) was estimated according to Kaplan-Meier and the EFS in the two treatment groups were compared by means of the log-rank test.</offsets></p><p><offsets xml_i="16647" xml_f="17275" txt_i="10887" txt_f="11515">The Cox regression model was adopted to evaluate the effects of the therapeutic regimen, adjusting for different confounding or prognostic factors and to evaluate the impact on prognosis of these factors. Both baseline and time-dependent covariates were considered in the multivariable model. The pH-lowering effect and the vaginal signs and symptoms were analysed using the Mann-Whitney test for inter-treatment comparisons and the Friedman test for intra-treatment analysis. Investigators’ and subjects’ judgements on the acceptability of the product in the two treatment groups were compared using the Wilcoxon Rank Sum test.</offsets></p><p><offsets xml_i="17282" xml_f="17370" txt_i="11516" txt_f="11604">All tests of hypotheses were performed using two-sided tests at a 5% significance level.</offsets></p></sec></sec><sec id="s3"><title><offsets xml_i="17406" xml_f="17413" txt_i="11607" txt_f="11614">Results</offsets></title><sec id="s3a"><title><offsets xml_i="17442" xml_f="17460" txt_i="11615" txt_f="11633">Patient population</offsets></title><p><offsets xml_i="17471" xml_f="17803" txt_i="11634" txt_f="11966">Overall, 142 women were randomised; 74 (52%) received ascorbic acid and the other 68 (48%) received placebo. The two groups were homogeneous for age, height and weight distribution. BV signs and symptoms (itching, burning, dysuria, odour, erythema, oedema and fissures) were fairly similar across treatment groups, as summarised in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="17835" xml_f="17842" txt_i="11966" txt_f="11973">Table 1</offsets></xref><offsets xml_i="17849" xml_f="17850" txt_i="11973" txt_f="11974">.</offsets></p><table-wrap id="T1" orientation="portrait" position="float"><label><offsets xml_i="17921" xml_f="17928" txt_i="11975" txt_f="11982">Table 1</offsets></label><caption><title><offsets xml_i="17952" xml_f="18052" txt_i="11982" txt_f="12082">Demographic and Baseline Characteristics in the Two Treatment Groups (Intention to Treat Population)</offsets></title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="18159" xml_f="18167" txt_i="12083" txt_f="12091">Variable</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="18213" xml_f="18222" txt_i="12091" txt_f="12100">Vitamin C</offsets><break></break><offsets xml_i="18237" xml_f="18245" txt_i="12100" txt_f="12108">(n = 74)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="18291" xml_f="18298" txt_i="12108" txt_f="12115">Placebo</offsets><break></break><offsets xml_i="18313" xml_f="18321" txt_i="12115" txt_f="12123">(n = 68)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="18367" xml_f="18372" txt_i="12123" txt_f="12128">Total</offsets><break></break><offsets xml_i="18387" xml_f="18396" txt_i="12128" txt_f="12137">(n = 142)</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18466" xml_f="18482" txt_i="12137" txt_f="12153">Demographic data</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="18528" xml_f="18530" txt_i="12154" txt_f="12156">74</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="18576" xml_f="18578" txt_i="12157" txt_f="12159">68</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="18624" xml_f="18627" txt_i="12160" txt_f="12163">142</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18682" xml_f="18705" txt_i="12164" txt_f="12187">Age (years) (mean ± SD)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="18751" xml_f="18761" txt_i="12188" txt_f="12198">31.2 ± 7.7</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="18807" xml_f="18817" txt_i="12199" txt_f="12209">31.0 ± 7.2</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="18863" xml_f="18873" txt_i="12210" txt_f="12220">31.1 ± 7.4</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18928" xml_f="18956" txt_i="12221" txt_f="12249">Body weight (kg) (mean ± SD)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19002" xml_f="19012" txt_i="12250" txt_f="12260">61.0 ± 9.4</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19058" xml_f="19068" txt_i="12261" txt_f="12271">60.5 ± 8.4</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19114" xml_f="19124" txt_i="12272" txt_f="12282">60.8 ± 8.9</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19179" xml_f="19202" txt_i="12283" txt_f="12306">Height (cm) (mean ± SD)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19248" xml_f="19259" txt_i="12307" txt_f="12318">165.3 ± 5.7</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19305" xml_f="19316" txt_i="12319" txt_f="12330">165.9 ± 6.2</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19362" xml_f="19373" txt_i="12331" txt_f="12342">165.6 ± 5.9</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19428" xml_f="19447" txt_i="12343" txt_f="12362">Itching (mean ± SD)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19493" xml_f="19503" txt_i="12363" txt_f="12373">0.15 ± 0.4</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19549" xml_f="19560" txt_i="12374" txt_f="12385">0.16 ± 0.37</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19606" xml_f="19617" txt_i="12386" txt_f="12397">0.15 ± 0.38</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19672" xml_f="19691" txt_i="12398" txt_f="12417">Burning (mean ± SD)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19737" xml_f="19748" txt_i="12418" txt_f="12429">0.14 ± 0.34</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19794" xml_f="19805" txt_i="12430" txt_f="12441">0.13 ± 0.38</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19851" xml_f="19862" txt_i="12442" txt_f="12453">0.13 ± 0.36</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19917" xml_f="19936" txt_i="12454" txt_f="12473">Dysuria (mean ± SD)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19982" xml_f="19993" txt_i="12474" txt_f="12485">0.03 ± 0.16</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20039" xml_f="20050" txt_i="12486" txt_f="12497">0.04 ± 0.21</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20096" xml_f="20107" txt_i="12498" txt_f="12509">0.04 ± 0.19</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20162" xml_f="20179" txt_i="12510" txt_f="12527">Odour (mean ± SD)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20225" xml_f="20235" txt_i="12528" txt_f="12538">0.09 ± 0.3</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20281" xml_f="20292" txt_i="12539" txt_f="12550">0.19 ± 0.43</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20338" xml_f="20349" txt_i="12551" txt_f="12562">0.14 ± 0.37</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20404" xml_f="20424" txt_i="12563" txt_f="12583">Erythema (mean ± SD)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20470" xml_f="20481" txt_i="12584" txt_f="12595">0.01 ± 0.12</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20527" xml_f="20538" txt_i="12596" txt_f="12607">0.06 ± 0.24</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20584" xml_f="20595" txt_i="12608" txt_f="12619">0.04 ± 0.19</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20650" xml_f="20668" txt_i="12620" txt_f="12638">Oedema (mean ± SD)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20714" xml_f="20725" txt_i="12639" txt_f="12650">0.00 ± 0.00</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20771" xml_f="20782" txt_i="12651" txt_f="12662">0.03 ± 0.17</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20828" xml_f="20839" txt_i="12663" txt_f="12674">0.01 ± 0.12</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20894" xml_f="20914" txt_i="12675" txt_f="12695">Fissures (mean ± SD)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20960" xml_f="20971" txt_i="12696" txt_f="12707">0.00 ± 0.00</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21017" xml_f="21028" txt_i="12708" txt_f="12719">0.01 ± 0.12</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21074" xml_f="21085" txt_i="12720" txt_f="12731">0.01 ± 0.08</offsets></td></tr></tbody></table></table-wrap></sec><sec id="s3b"><title><offsets xml_i="21151" xml_f="21193" txt_i="12733" txt_f="12775">Proportion of patients free of BV relapses</offsets></title><p><offsets xml_i="21204" xml_f="21575" txt_i="12776" txt_f="13147">The proportion of women having a BV recurrence in the ITT population during the first 3 months was 6.8% in the vitamin C group (5/74) and 14.7% (10/68) in the placebo group, but the difference between the groups was not statistically significant. After 6 months of treatment, the recurrence rate was 16.2% in the vitamin C group compared with 32.4% in the placebo group (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="21605" xml_f="21611" txt_i="13147" txt_f="13153">Fig. 1</offsets></xref><offsets xml_i="21618" xml_f="22052" txt_i="13153" txt_f="13587">), which was statistically significant (P = 0.024, chi-square test). The results were confirmed by the O.R. that represents the risk of a recurrent episode of BV in the group treated with vitamin C in comparison to the placebo group. After six cycles of prophylaxis, the O.R. was 0.405 (95% confidence interval (CI) = 0.182 - 0.901). The result was statistically significant since the 95% CI of the O.R. did not include the value ‘1’.</offsets></p><fig id="F1" orientation="portrait" position="float"><label><offsets xml_i="22116" xml_f="22124" txt_i="13588" txt_f="13596">Figure 1</offsets></label><caption><p><offsets xml_i="22144" xml_f="22283" txt_i="13596" txt_f="13735">Proportion of patients free of BV relapse after three-cycle and six-cycle periods of prophylaxis (Intention-to-treat population, n = 142). </offsets></p></caption><graphic xlink:href="jocmr-05-309-g001"></graphic></fig><p><offsets xml_i="22356" xml_f="22392" txt_i="13736" txt_f="13772">The Kaplan-Meier survival analysis (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="22422" xml_f="22428" txt_i="13772" txt_f="13778">Fig. 2</offsets></xref><offsets xml_i="22435" xml_f="22762" txt_i="13778" txt_f="14105">), probability of being free of BV relapse in the two groups during the period of prophylaxis, became statistically significant starting from the 5-month time point (P = 0.039 vitamin C vs. placebo, log-rank test); the significant difference was maintained and increased at the 6-month evaluation (end of treatment, P = 0.029).</offsets></p><fig id="F2" orientation="portrait" position="float"><label><offsets xml_i="22826" xml_f="22834" txt_i="14106" txt_f="14114">Figure 2</offsets></label><caption><p><offsets xml_i="22854" xml_f="22965" txt_i="14114" txt_f="14225">Kaplan-Meier survival analysis after six-cycle period of prophylaxis (Intention-to-treat population, n = 142). </offsets></p></caption><graphic xlink:href="jocmr-05-309-g002"></graphic></fig></sec><sec id="s3c"><title><offsets xml_i="23062" xml_f="23117" txt_i="14227" txt_f="14282">Effect of prophylaxis on vaginal signs, symptoms and pH</offsets></title><p><offsets xml_i="23128" xml_f="23560" txt_i="14283" txt_f="14715">BV signs and symptoms did not show any statistically significant differences through the treatment study period (from baseline to the follow-up visit), or in comparison of the treatment groups at the evaluated time points. The pH-lowering effect of vitamin C was detected after a prophylaxis period of 3 months, with a reduction of 3.8% compared with the baseline value and becoming statistically significant compared with placebo (</offsets><xref ref-type="fig" rid="F3"><offsets xml_i="23590" xml_f="23596" txt_i="14715" txt_f="14721">Fig. 3</offsets></xref><offsets xml_i="23603" xml_f="23914" txt_i="14721" txt_f="15032">) after four cycles of treatments (P = 0.032, Mann-Whitney test). The acceptability of treatment was judged as very good or good by 80.8% and 76.5% of investigators for the vitamin C and placebo groups, respectively, and by 76.7% of patients treated with vitamin C and by 75.0% of patients treated with placebo.</offsets></p><fig id="F3" orientation="portrait" position="float"><label><offsets xml_i="23978" xml_f="23986" txt_i="15033" txt_f="15041">Figure 3</offsets></label><caption><p><offsets xml_i="24006" xml_f="24097" txt_i="15041" txt_f="15132"> (a). Vaginal pH-lowering effect of vitamin C; (b): Vaginal pH-lowering effect of placebo. </offsets></p></caption><graphic xlink:href="jocmr-05-309-g003"></graphic></fig></sec><sec id="s3d"><title><offsets xml_i="24194" xml_f="24200" txt_i="15134" txt_f="15140">Safety</offsets></title><p><offsets xml_i="24211" xml_f="24491" txt_i="15141" txt_f="15421">The safety of vitamin C treatment was similar to placebo. The most common treatment-related adverse events (AEs) in both groups were local reactions such as itching, burning and skin irritation (n = 3 in the vitamin C group; n = 4 in the placebo group). All the AEs are showed in </offsets><xref ref-type="table" rid="T2"><offsets xml_i="24523" xml_f="24530" txt_i="15421" txt_f="15428">Table 2</offsets></xref><offsets xml_i="24537" xml_f="24538" txt_i="15428" txt_f="15429">.</offsets></p><table-wrap id="T2" orientation="portrait" position="float"><label><offsets xml_i="24609" xml_f="24616" txt_i="15430" txt_f="15437">Table 2</offsets></label><caption><title><offsets xml_i="24640" xml_f="24689" txt_i="15437" txt_f="15486">Patients With at Least One AE (Safety Population)</offsets></title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"><offsets xml_i="24796" xml_f="24809" txt_i="15487" txt_f="15500">Adverse event</offsets></th><th align="left" colspan="2" rowspan="1"><offsets xml_i="24855" xml_f="24870" txt_i="15500" txt_f="15515">Treatment group</offsets><hr></hr></th></tr><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="24934" xml_f="24952" txt_i="15515" txt_f="15533">Vitamin C (n = 74)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="24998" xml_f="25014" txt_i="15533" txt_f="15549">Placebo (n = 68)</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="25084" xml_f="25117" txt_i="15549" txt_f="15582">Burning, itching, skin irritation</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25163" xml_f="25171" txt_i="15583" txt_f="15591">3 (4.0%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25217" xml_f="25225" txt_i="15592" txt_f="15600">4 (5.9%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="25280" xml_f="25291" txt_i="15601" txt_f="15612">Candidiasis</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25337" xml_f="25345" txt_i="15613" txt_f="15621">1 (1.4%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25391" xml_f="25399" txt_i="15622" txt_f="15630">1 (1.5%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="25454" xml_f="25462" txt_i="15631" txt_f="15639">Cystitis</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25508" xml_f="25509" txt_i="15640" txt_f="15641">-</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25555" xml_f="25563" txt_i="15642" txt_f="15650">1 (1.5%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="25618" xml_f="25624" txt_i="15651" txt_f="15657">Nausea</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25670" xml_f="25671" txt_i="15658" txt_f="15659">-</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25717" xml_f="25725" txt_i="15660" txt_f="15668">1 (1.5%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="25780" xml_f="25790" txt_i="15669" txt_f="15679">Bronchitis</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25836" xml_f="25844" txt_i="15680" txt_f="15688">1 (1.4%)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="25890" xml_f="25891" txt_i="15689" txt_f="15690">-</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="25946" xml_f="25962" txt_i="15691" txt_f="15707">Major depression</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26008" xml_f="26009" txt_i="15708" txt_f="15709">-</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26055" xml_f="26063" txt_i="15710" txt_f="15718">1 (1.5%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="26118" xml_f="26121" txt_i="15719" txt_f="15722">Flu</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26167" xml_f="26168" txt_i="15723" txt_f="15724">-</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="26214" xml_f="26222" txt_i="15725" txt_f="15733">1 (1.5%)</offsets></td></tr></tbody></table></table-wrap><p><offsets xml_i="26264" xml_f="26455" txt_i="15734" txt_f="15925">Local tolerability was judged as very good or good by 75.3% of patients and 86.0% of investigators after vitamin C treatment and by 76.6% of patients and 82.0% of investigators after placebo.</offsets></p></sec></sec><sec id="s4"><title><offsets xml_i="26491" xml_f="26501" txt_i="15928" txt_f="15938">Discussion</offsets></title><p><offsets xml_i="26512" xml_f="27195" txt_i="15939" txt_f="16622">A therapeutic approach in the treatment of BV relapse is to re-establish and maintain the physiological acidity of the vagina, as the growth of anaerobes and other faecal bacteria is inhibited by low pH. Attempts to achieve this via re-colonisation with exogenous lactobacilli have not been successful. Another, more accepted approach is to reduce vaginal pH, in order to create a negative environment for pathogen growth and to achieve long-lasting normalisation of vaginal flora using intravaginal ascorbic acid (vitamin C). The use of antibiotics may induce resistance in the pool of bacteria recognised to cause BV and, conversely, could affect the normal flora of lactobacilli [</offsets><xref ref-type="bibr" rid="R09"><offsets xml_i="27227" xml_f="27228" txt_i="16622" txt_f="16623">9</offsets></xref><offsets xml_i="27235" xml_f="27343" txt_i="16623" txt_f="16731">], favouring recurrence within a few weeks in over 70% of women taking antibiotics for bacterial vaginosis [</offsets><xref ref-type="bibr" rid="R18"><offsets xml_i="27375" xml_f="27377" txt_i="16731" txt_f="16733">18</offsets></xref><offsets xml_i="27384" xml_f="27856" txt_i="16733" txt_f="17205">]. Ascorbic acid (250 mg, in a silicone carrier that ensures prolonged action) plays a vital role in maintaining low vaginal pH values and enhances healing processes in the vaginal ecosystem - recolonisation with lactic acid bacteria. The mechanism of action is simple: through the lowering of vaginal pH to the physiological level of 3.8 - 4.5, anaerobic overgrowth is inhibited and the conditions for the re-growth of physiological lactobacilli flora are re-established.</offsets></p><p><offsets xml_i="27863" xml_f="28715" txt_i="17206" txt_f="18058">The results of the present study show that 250 mg ascorbic acid vaginal tablets taken 6 days per month safely halves the risk of BV recurrence from 32.4% to 16.2% during a 6-month prophylactic treatment. The O.R. confirms that subjects treated with placebo had a doubled risk of BV recurrence compared with the group of subjects treated with vitamin C. Considering the time to the first BV relapse, treatment of at least five cycles is necessary in order to reduce, at a significant level, the risk of BV recurrence. As this was a prophylaxis study, in women who at the screening visit were healthy and who terminated the study in case of relapse, a between-treatment difference in clinical parameters was not expected. At the same time, differences in pH were not expected but conversely, a reduction in pH was noted for 3-month and 6-month treatment.</offsets></p><p><offsets xml_i="28722" xml_f="28987" txt_i="18059" txt_f="18324">In conclusion, regular use of silicon-coated vitamin C (250 mg) tablets, after the standard antibiotic treatment for BV, protects women by reducing the risk of recurrence probably by re-establishing the normal lactobacilli flora that is able to maintain vaginal pH.</offsets></p></sec></body><back><ack><p>The contribution of the following persons to the investigation is gratefully acknowledged: Medi Service S.r.l., Agrate Brianza, Milan, Italy; R. Fasani and G. Reggiardo.</p></ack><sec id="s5"><title>Conflicts of Interest and Source of Funding</title><p>Vladislav N. Krasnopolsky, Vera N. Prilepskaya, Franco Polatti, Nina V. Zarochentseva, and Guldana R. Bayramova received honoraria from Polichem S.A. as study investigators. Maurizio Caserini and Renata Palmieri are employees of Polichem S.A.</p><p>Polichem S.A. sponsored all phases of the study and supplied the trial product.</p></sec><sec id="s6"><title>Abbreviations</title><def-list><def-item><term>AE</term><def><p>adverse event</p></def></def-item><def-item><term>BV</term><def><p>bacterial vaginosis</p></def></def-item><def-item><term>EFS</term><def><p>event-free survival curve</p></def></def-item><def-item><term>GCP</term><def><p>good clinical practice</p></def></def-item><def-item><term>HIV</term><def><p>human immunodeficiency virus</p></def></def-item><def-item><term>ITT</term><def><p>intention-to-treat population</p></def></def-item><def-item><term>LOCF</term><def><p>last observation carried forward</p></def></def-item><def-item><term>O.R.</term><def><p>odds ratio</p></def></def-item><def-item><term>SD</term><def><p>standard deviation</p></def></def-item></def-list></sec><ref-list><title>References</title><ref id="R01"><label>1</label><element-citation publication-type="journal"><name><surname>Allsworth</surname><given-names>JE</given-names></name><name><surname>Peipert</surname><given-names>JF</given-names></name><article-title>Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data</article-title><source>Obstet Gynecol</source><year>2007</year><volume>109</volume><issue>1</issue><fpage>114</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">17197596</pub-id></element-citation></ref><ref id="R02"><label>2</label><element-citation publication-type="journal"><name><surname>Donders</surname><given-names>G</given-names></name><article-title>Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review</article-title><source>Obstet Gynecol Surv</source><year>2010</year><volume>65</volume><issue>7</issue><fpage>462</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">20723268</pub-id></element-citation></ref><ref id="R03"><label>3</label><element-citation publication-type="journal"><name><surname>Sobel</surname><given-names>JD</given-names></name><article-title>Bacterial vaginosis</article-title><source>Annu Rev Med</source><year>2000</year><volume>51</volume><fpage>349</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">10774469</pub-id></element-citation></ref><ref id="R04"><label>4</label><element-citation publication-type="journal"><name><surname>Swidsinski</surname><given-names>A</given-names></name><name><surname>Mendling</surname><given-names>W</given-names></name><name><surname>Loening-Baucke</surname><given-names>V</given-names></name><name><surname>Ladhoff</surname><given-names>A</given-names></name><name><surname>Swidsinski</surname><given-names>S</given-names></name><name><surname>Hale</surname><given-names>LP</given-names></name><name><surname>Lochs</surname><given-names>H</given-names></name><article-title>Adherent biofilms in bacterial vaginosis</article-title><source>Obstet Gynecol</source><year>2005</year><volume>106</volume><issue>5 Pt 1</issue><fpage>1013</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">16260520</pub-id></element-citation></ref><ref id="R05"><label>5</label><element-citation publication-type="journal"><name><surname>Tool</surname><given-names>GO</given-names></name><name><surname>Kaplan</surname><given-names>HB</given-names></name><name><surname>Kolter</surname><given-names>R</given-names></name><article-title>Biofilm formation as microbial development</article-title><source>Ann Rev Microbiol</source><year>2000</year><volume>54</volume><fpage>49</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">11018124</pub-id></element-citation></ref><ref id="R06"><label>6</label><element-citation publication-type="journal"><name><surname>Swidsinski</surname><given-names>A</given-names></name><name><surname>Mendling</surname><given-names>W</given-names></name><name><surname>Loening-Baucke</surname><given-names>V</given-names></name><name><surname>Swidsinski</surname><given-names>S</given-names></name><name><surname>Dorffel</surname><given-names>Y</given-names></name><name><surname>Scholze</surname><given-names>J</given-names></name><name><surname>Lochs</surname><given-names>H</given-names></name><etal>et al</etal><article-title>An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole</article-title><source>Am J Obstet Gynecol</source><year>2008</year><volume>198</volume><issue>1</issue><fpage>97.e1</fpage><lpage>97.e6</lpage><pub-id pub-id-type="pmid">18005928</pub-id></element-citation></ref><ref id="R07"><label>7</label><element-citation publication-type="journal"><name><surname>Hay</surname><given-names>P</given-names></name><article-title>Recurrent Bacterial Vaginosis</article-title><source>Curr Infect Dis Rep</source><year>2000</year><volume>2</volume><issue>6</issue><fpage>506</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">11095900</pub-id></element-citation></ref><ref id="R08"><label>8</label><element-citation publication-type="journal"><name><surname>Polatti</surname><given-names>F</given-names></name><article-title>Bacterial vaginosis, Atopobium vaginae and nifuratel</article-title><source>Curr Clin Pharmacol</source><year>2012</year><volume>7</volume><issue>1</issue><fpage>36</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">22082330</pub-id></element-citation></ref><ref id="R09"><label>9</label><element-citation publication-type="journal"><name><surname>Togni</surname><given-names>G</given-names></name><name><surname>Battini</surname><given-names>V</given-names></name><name><surname>Bulgheroni</surname><given-names>A</given-names></name><name><surname>Mailland</surname><given-names>F</given-names></name><name><surname>Caserini</surname><given-names>M</given-names></name><name><surname>Mendling</surname><given-names>W</given-names></name><article-title>In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis?</article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><issue>5</issue><fpage>2490</fpage><lpage>2492</lpage><pub-id pub-id-type="pmid">21321147</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Bent</surname><given-names>SJ</given-names></name><name><surname>Schneider</surname><given-names>MG</given-names></name><name><surname>Davis</surname><given-names>CC</given-names></name><name><surname>Islam</surname><given-names>MR</given-names></name><name><surname>Forney</surname><given-names>LJ</given-names></name><article-title>Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods</article-title><source>Microbiology</source><year>2004</year><volume>150</volume><issue>Pt 8</issue><fpage>2565</fpage><lpage>2573</lpage><pub-id pub-id-type="pmid">15289553</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><name><surname>Marconi</surname><given-names>C</given-names></name><name><surname>Cruciani</surname><given-names>F</given-names></name><name><surname>Vitali</surname><given-names>B</given-names></name><name><surname>Donders</surname><given-names>GG</given-names></name><article-title>Correlation of Atopobium vaginae Amount With Bacterial Vaginosis Markers</article-title><source>J Low Genit Tract Dis</source><year>2012</year><volume>16</volume><issue>2</issue><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">22371042</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><name><surname>Polatti</surname><given-names>F</given-names></name><name><surname>Rampino</surname><given-names>M</given-names></name><name><surname>Magnani</surname><given-names>P</given-names></name><name><surname>Mascarucci</surname><given-names>P</given-names></name><article-title>Vaginal pH-lowering effect of locally applied vitamin C in subjects with high vaginal pH</article-title><source>Gynecol Endocrinol</source><year>2006</year><volume>22</volume><issue>4</issue><fpage>230</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">16723311</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><name><surname>Petersen</surname><given-names>EE</given-names></name><name><surname>Magnani</surname><given-names>P</given-names></name><article-title>Efficacy and safety of vitamin C vaginal tablets in the treatment of non-specific vaginitis. A randomised, double blind, placebo-controlled study</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2004</year><volume>117</volume><issue>1</issue><fpage>70</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">15474248</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><name><surname>Petersen</surname><given-names>EE</given-names></name><name><surname>Genet</surname><given-names>M</given-names></name><name><surname>Caserini</surname><given-names>M</given-names></name><name><surname>Palmieri</surname><given-names>R</given-names></name><article-title>Efficacy of vitamin C vaginal tablets in the treatment of bacterial vaginosis: a randomised, double blind, placebo controlled clinical trial</article-title><source>Arzneimittelforschung</source><year>2011</year><volume>61</volume><issue>4</issue><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">21650086</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><name><surname>Abbaspour</surname><given-names>Z</given-names></name><name><surname>Goodarzy</surname><given-names>F</given-names></name><name><surname>Abbaspour</surname><given-names>MR</given-names></name><article-title>Comparison effect of vitamin C vaginal tablet and metronidazole vaginal gel on treatment and relapse of bacterial vaginosis</article-title><source>Afr J Pharm Pharmacol</source><year>2010</year><volume>4</volume><fpage>484</fpage><lpage>489</lpage></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><name><surname>Wilson</surname><given-names>J</given-names></name><article-title>Managing recurrent bacterial vaginosis</article-title><source>Sex Transm Infect</source><year>2004</year><volume>80</volume><issue>1</issue><fpage>8</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">14755028</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><name><surname>Amsel</surname><given-names>R</given-names></name><name><surname>Totten</surname><given-names>PA</given-names></name><name><surname>Spiegel</surname><given-names>CA</given-names></name><name><surname>Chen</surname><given-names>KC</given-names></name><name><surname>Eschenbach</surname><given-names>D</given-names></name><name><surname>Holmes</surname><given-names>KK</given-names></name><article-title>Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations</article-title><source>Am J Med</source><year>1983</year><volume>74</volume><issue>1</issue><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">6600371</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><name><surname>Bradshaw</surname><given-names>CS</given-names></name><name><surname>Morton</surname><given-names>AN</given-names></name><name><surname>Hocking</surname><given-names>J</given-names></name><name><surname>Garland</surname><given-names>SM</given-names></name><name><surname>Morris</surname><given-names>MB</given-names></name><name><surname>Moss</surname><given-names>LM</given-names></name><name><surname>Horvath</surname><given-names>LB</given-names></name><etal>et al</etal><article-title>High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence</article-title><source>J Infect Dis</source><year>2006</year><volume>193</volume><issue>11</issue><fpage>1478</fpage><lpage>1486</lpage><pub-id pub-id-type="pmid">16652274</pub-id></element-citation></ref></ref-list></back></article>